List view / Grid view
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Scientists in Hong Kong have developed a novel optical technique that facilitates accurate tracking of hemogenic endothelium cells in zebrafish embryos, providing new insights into the mechanisms of blood formation and potential new understanding of diseases such as leukaemia.
Researchers have identified that in leukaemia, mutated receptors allow blood stem cells to activate one another without the proper signal and suggest this discovery could lead to targeted novel therapies.
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies.
PROTAC drugs that safely and effectively target leukaemia and lymphoma cells have been developed by researchers.
Researchers have reprogrammed CAR T cells to prevent them becoming exhausted after prolonged activity, presenting a possible new therapy for solid tumours.
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
A new study shows the ways in which epigenetic mechanisms control the activity of genes and may have an impact on the future treatment of certain cancers.
Researchers have found that inhibiting a kinase in mice leads to the death of prostate cancer cells, providing a potential therapeutic target.
Researchers have found a molecule, which when deleted, increases leukaemia sensitivity to natural killer cells and is a drug target.
Researchers have successfully created a multi-organ in vitro model to test toxicity and efficacy of drugs.
A single leukemic cell has become resistant to CAR-T therapy after unknowingly engineered with the leukemia-targeting CAR lentivirus...
Silencing the gene behind the production of HSP90, a target in the HSF1 pathway, effectively kills leukaemia cells, without affecting healthy cells...
In a new study based on mouse cells, researchers have identified several new potential targets using state-of-the-art technology, many of which could be employed for future treatment of different types of cancers and diseases.
